Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Deals

Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies

Fineline Cube Sep 11, 2024

Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage...

Company Deals

Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector

Fineline Cube Sep 11, 2024

Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with...

Company Drug

Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC

Fineline Cube Sep 11, 2024

Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...

Company Deals

ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal

Fineline Cube Sep 11, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment...

Company Drug

Nuance Pharma Completes Enrollment for Phase III COPD Trial of Ohtuvayre in China

Fineline Cube Sep 11, 2024

Nuance Pharma, a China-based pharmaceutical company, has announced the completion of patient enrollment for the...

Company Drug

Innovent Biologics Presents Promising Phase I Data for IBI363 in Advanced NSCLC at WCLC

Fineline Cube Sep 11, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has unveiled Phase...

Company Drug

Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA

Fineline Cube Sep 11, 2024

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...

Company Drug

Duality Biologics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors

Fineline Cube Sep 11, 2024

Duality Biologics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with...

Company Medical Device

Medtronic Secures China Market Approval for Pulsed Electric Field Atrial Fibrillation Treatment Devices

Fineline Cube Sep 11, 2024

Medtronic (NYSE: MDT), the US-Irish medical technology giant, has announced that it has received approvals...

Company Drug Legal / IP

AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute

Fineline Cube Sep 11, 2024

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie...

Company Drug

Terns Pharmaceuticals’ Oral GLP-1R Agonist TERN-601 Shows Promising Weight Loss Results in Phase I Trial

Fineline Cube Sep 10, 2024

Terns Pharmaceuticals Inc. (NASDAQ: TERN), a U.S.-based biotechnology company originally spun out from Eli Lilly’s...

Company Drug

GSK’s Nucala Shows Promise in Phase III COPD Trial, MATINEE Results Positive

Fineline Cube Sep 10, 2024

GSK plc (LON: GSK, NYSE: GSK), a leading UK-based pharmaceutical company, has announced positive results...

Company Legal / IP

US House Approves Biosecure Act with Implications for Chinese Biotech Firms

Fineline Cube Sep 10, 2024

The US House of Representatives has taken a decisive step towards tightening biosecurity measures, voting...

Company Drug

CIRC’s Subsidiary HTA Co., Ltd. Secures NMPA Approval for Sodium Fluoride [18F] for Bone Imaging

Fineline Cube Sep 10, 2024

China Isotope & Radiation Corporation’s (CIRC) subsidiary, HTA Co., Ltd. (HKG: 1763), has announced that...

Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China

Fineline Cube Sep 10, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Deals

Beijing Centergate Technologies and Bestcomm Pharmaceutical Form Strategic Partnership in Multiple Medical Fields

Fineline Cube Sep 10, 2024

Beijing Centergate Technologies (Holding) Co., Ltd (CENTEK, SHE: 000931), a pharmaceutical manufacturing company in China,...

Company Drug

Jiangsu Hengrui’s ANGPTL3 Inhibitor SHR-1918 Earns Breakthrough Designation for HoFH Treatment

Fineline Cube Sep 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries

Fineline Cube Sep 10, 2024

Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...

Company Deals

JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development

Fineline Cube Sep 10, 2024

JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200...

Company Medical Device

Amoy Diagnostics’ AiHuiJie Lung Cancer Companion Diagnostic Receives NMPA Approval

Fineline Cube Sep 10, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a biopharmaceutical company based in China, has announced...

Posts pagination

1 … 291 292 293 … 658

Recent updates

  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.